Summary & Overview
CPT 67227: Retinal Ablative Therapy for Proliferative Retinopathy
CPT code 67227 represents retinal ablative therapy using cryotherapy or diathermy to destroy proliferative retinal neovascularization and associated fibrous tissue. This procedure is clinically important because untreated proliferative retinopathies, commonly seen in diabetic retinopathy, can progress to vitreous hemorrhage, tractional retinal detachment, and irreversible vision loss. Nationally, procedures coded with 67227 are relevant to ophthalmology surgical services and to payers managing complications of chronic disease.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for 67227, the typical sites of service, and an outline of the procedural intent. The publication also covers payer coverage considerations and commonly used modifiers (list provided), benchmarking concepts, and how 67227 relates to management of proliferative retinopathy in outpatient surgical and hospital settings.
This summary equips clinicians, billing staff, and policy analysts with the foundational understanding of what 67227 denotes, why it matters from a clinical and utilization perspective, and which national payers commonly cover services described by this code. Data not available in the input is explicitly noted where applicable in detailed sections.
Billing Code Overview
CPT code 67227 describes a surgical procedure to destroy abnormal, proliferative retinal blood vessels and associated fibrous tissue using freezing (cryotherapy) or heating (diathermy) probes. This treatment is used when new, fragile vessels grow on or between the layers of the retina — a process that can lead to vitreous hemorrhage, tractional retinal detachment, and vision loss if untreated. The procedure may be performed for diabetic retinopathy and other proliferative retinopathies.
-
Service type: Retinal ablative therapy (cryotherapy or diathermy) for proliferative retinopathy
-
Typical site of service: Ophthalmology surgical suite or hospital outpatient department where ocular procedures are performed
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with longstanding type 2 diabetes mellitus presents to a tertiary ophthalmology clinic with progressive vision changes and ophthalmic exam findings consistent with proliferative diabetic retinopathy. Examination with slit-lamp and dilated fundus exam, supplemented by fluorescein angiography and optical coherence tomography, demonstrates extensive neovascularization of the retina and preretinal fibrous proliferation with risk of vitreous hemorrhage and tractional retinal detachment. The ophthalmologist schedules an in‑office or ambulatory surgery center procedure to ablate neovascularization using cryotherapy or diathermy probes (CPT 67227).
Clinical workflow:
-
Patient evaluation and informed consent, including review of medical comorbidities and anticoagulation status.
-
Pre-procedure photography and imaging (fundus photos, OCT, fluorescein angiography) to document baseline disease.
-
Procedure performed under local, regional block, monitored anesthesia care, or general anesthesia depending on complexity and patient factors; probes are applied transsclerally or via pars plana to destroy neovascular tissue.
-
Post-procedure observation with intraocular pressure checks and topical medications; scheduled follow-up visits to assess response and need for additional laser, intravitreal pharmacotherapy, or vitrectomy.
-
Documentation includes laterality (
RT/LT), anesthesia type, operative note describing cryotherapy or diathermy application, number and location of treatment sites, complications, and post-procedure instructions.